Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: Clin Cancer Res. 2012 Dec 18;19(3):657–667. doi: 10.1158/1078-0432.CCR-11-1446

Figure 3. Combination therapy with BRAF and PI3K/AKT inhibitors is synergistic.

Figure 3

A. HT29 cells were treated with PLX4720 (0.15 µM) alone, or in combination with the PI3K inhibitors LY294002 (5 µM) or GDC0941 (0.5 µM) for 72 h and cell count was assessed. The data represent mean values ±SD (*represents P <0.001 compared to either single agent). B. Isobologram demonstrates synergy of the combination of PLX4720 and PI3K inhibitors in CRC cell lines. Regions to the bottom left of the figure represent increasing degrees of synergy. C. Cells were incubated for 24 h with PLX4720 (1 µM), LY294002 (15 µM) or their combination, prior to cell cycle analysis. The data represent mean values from three independent experiments. D. Efficacy of MK2206 combined with PLX4720 on established LS411N xenografts is greater than either agent alone. Mice were administered PLX4720 chow (TGI 20%), MK2206 120 mg/kg by oral gavage three times a week (TGI 31%), or a combination (TGI 62%) (*P<0.01 compared to PLX4720 alone; #P< 0.05 compared to MK-2206 alone).